JP2017534673A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534673A5 JP2017534673A5 JP2017533742A JP2017533742A JP2017534673A5 JP 2017534673 A5 JP2017534673 A5 JP 2017534673A5 JP 2017533742 A JP2017533742 A JP 2017533742A JP 2017533742 A JP2017533742 A JP 2017533742A JP 2017534673 A5 JP2017534673 A5 JP 2017534673A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- glutathione
- modulator compound
- glutathione peroxidase
- cyclodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 36
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 28
- 102000006587 Glutathione peroxidase Human genes 0.000 claims description 23
- 108700016172 Glutathione peroxidases Proteins 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 22
- 229940002612 prodrug Drugs 0.000 claims description 22
- 208000028017 Psychotic disease Diseases 0.000 claims description 19
- 108010024636 Glutathione Proteins 0.000 claims description 18
- 229960003180 glutathione Drugs 0.000 claims description 18
- 229920000858 Cyclodextrin Polymers 0.000 claims description 16
- 239000001116 FEMA 4028 Substances 0.000 claims description 16
- 229960004853 betadex Drugs 0.000 claims description 16
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims description 16
- 229960001534 risperidone Drugs 0.000 claims description 16
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 16
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 16
- 230000000561 anti-psychotic effect Effects 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- PMXMIIMHBWHSKN-LJQANCHMSA-N (R)-paliperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCC[C@@H](O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-LJQANCHMSA-N 0.000 claims description 8
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims description 8
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 claims description 8
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 8
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000164 antipsychotic agent Substances 0.000 claims description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 8
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 8
- 229960001076 chlorpromazine Drugs 0.000 claims description 8
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 8
- 229950010033 ebselen Drugs 0.000 claims description 8
- 229960002690 fluphenazine Drugs 0.000 claims description 8
- 229940003380 geodon Drugs 0.000 claims description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 8
- 229940036674 latuda Drugs 0.000 claims description 8
- 229960001432 lurasidone Drugs 0.000 claims description 8
- 229960005017 olanzapine Drugs 0.000 claims description 8
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 8
- 229960000762 perphenazine Drugs 0.000 claims description 8
- -1 phenylacetyl Chemical group 0.000 claims description 8
- 229960004431 quetiapine Drugs 0.000 claims description 8
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims description 8
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims description 8
- 229910052711 selenium Inorganic materials 0.000 claims description 8
- 239000011669 selenium Substances 0.000 claims description 8
- 229940035004 seroquel Drugs 0.000 claims description 8
- 229940110851 tolazine Drugs 0.000 claims description 8
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 claims description 8
- 229960000607 ziprasidone Drugs 0.000 claims description 8
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
- 206010026749 Mania Diseases 0.000 claims description 4
- ZFAHNWWNDFHPOH-YFKPBYRVSA-N S-allylcysteine Chemical compound OC(=O)[C@@H](N)CSCC=C ZFAHNWWNDFHPOH-YFKPBYRVSA-N 0.000 claims description 4
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 claims description 4
- 229960004308 acetylcysteine Drugs 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000036542 oxidative stress Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical class OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 claims description 4
- UJCHIZDEQZMODR-BYPYZUCNSA-N (2r)-2-acetamido-3-sulfanylpropanamide Chemical compound CC(=O)N[C@@H](CS)C(N)=O UJCHIZDEQZMODR-BYPYZUCNSA-N 0.000 claims description 2
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- ZFAHNWWNDFHPOH-UHFFFAOYSA-N S-Allyl-L-cystein Natural products OC(=O)C(N)CSCC=C ZFAHNWWNDFHPOH-UHFFFAOYSA-N 0.000 claims description 2
- ULXKXLZEOGLCRJ-BYPYZUCNSA-N S-ethyl-L-cysteine zwitterion Chemical compound CCSC[C@H](N)C(O)=O ULXKXLZEOGLCRJ-BYPYZUCNSA-N 0.000 claims description 2
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 claims description 2
- WAAGBMYUYFBZIW-UHFFFAOYSA-N S-propylcysteine Chemical compound CCCSCC(N)C(O)=O WAAGBMYUYFBZIW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229940005529 antipsychotics Drugs 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 239000003196 psychodysleptic agent Substances 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021130488A JP2021181473A (ja) | 2014-09-15 | 2021-08-10 | 精神病性障害を治療するための方法および組成物 |
| JP2023168970A JP2023169413A (ja) | 2014-09-15 | 2023-09-29 | 精神病性障害を治療するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050635P | 2014-09-15 | 2014-09-15 | |
| US62/050,635 | 2014-09-15 | ||
| PCT/US2015/050255 WO2016044314A1 (en) | 2014-09-15 | 2015-09-15 | Methods and compositions for treating psychotic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130488A Division JP2021181473A (ja) | 2014-09-15 | 2021-08-10 | 精神病性障害を治療するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017534673A JP2017534673A (ja) | 2017-11-24 |
| JP2017534673A5 true JP2017534673A5 (enExample) | 2018-10-25 |
Family
ID=55533760
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533742A Pending JP2017534673A (ja) | 2014-09-15 | 2015-09-15 | 精神病性障害を治療するための方法および組成物 |
| JP2021130488A Pending JP2021181473A (ja) | 2014-09-15 | 2021-08-10 | 精神病性障害を治療するための方法および組成物 |
| JP2023168970A Pending JP2023169413A (ja) | 2014-09-15 | 2023-09-29 | 精神病性障害を治療するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021130488A Pending JP2021181473A (ja) | 2014-09-15 | 2021-08-10 | 精神病性障害を治療するための方法および組成物 |
| JP2023168970A Pending JP2023169413A (ja) | 2014-09-15 | 2023-09-29 | 精神病性障害を治療するための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20170246148A1 (enExample) |
| EP (1) | EP3194027A4 (enExample) |
| JP (3) | JP2017534673A (enExample) |
| KR (2) | KR20230107890A (enExample) |
| AU (4) | AU2015317877A1 (enExample) |
| CA (1) | CA2961380A1 (enExample) |
| WO (1) | WO2016044314A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6308134B2 (ja) * | 2012-12-27 | 2018-04-11 | ソニー株式会社 | 細胞分析システム、細胞分析プログラム及び細胞分析方法 |
| EP3037514B1 (en) | 2013-11-08 | 2018-12-26 | Sony Corporation | Cell analysis system, cell analysis program, and cell analysis method |
| KR102474830B1 (ko) * | 2016-05-18 | 2022-12-06 | 사운드 파마슈티칼스 인코퍼레이티드 | 중이염의 치료 |
| CN107362144B (zh) * | 2017-08-03 | 2020-04-17 | 华侨大学 | 一种鲁拉西酮脑靶向脂质体注射剂及其制备方法 |
| GB201717629D0 (en) | 2017-10-26 | 2017-12-13 | Univ Oxford Innovation Ltd | Treatment of unipolar depressive disorder |
| CN111432813B (zh) * | 2017-11-14 | 2024-01-09 | 爱思开生物制药株式会社 | 用于预防、减轻、或治疗精神分裂症的包含氨基甲酸酯化合物的共混物 |
| AU2020448022B2 (en) * | 2020-05-09 | 2024-05-09 | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. | Treatment of adverse effects caused by atypical antipsychotics |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2650204A1 (en) * | 1996-12-31 | 1998-07-09 | Harry B. Demopoulos | Pharmaceutical preparations of glutathione and methods of administration thereof |
| JP4684553B2 (ja) * | 2001-09-27 | 2011-05-18 | ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア | 生理学的過程の調節およびこれに有用な薬剤 |
| KR20080028357A (ko) * | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드) |
| US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20110046090A1 (en) * | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| ZA200902203B (en) * | 2006-10-23 | 2010-08-25 | Mental Health Res Inst Of Vict | Combination therapy |
| CA2842106A1 (en) * | 2011-07-28 | 2013-01-31 | Promentis Pharmaceuticals, Inc. | Cysteine prodrugs |
-
2015
- 2015-09-15 WO PCT/US2015/050255 patent/WO2016044314A1/en not_active Ceased
- 2015-09-15 EP EP15842621.3A patent/EP3194027A4/en active Pending
- 2015-09-15 CA CA2961380A patent/CA2961380A1/en active Pending
- 2015-09-15 KR KR1020237022184A patent/KR20230107890A/ko not_active Ceased
- 2015-09-15 KR KR1020177010114A patent/KR20170066432A/ko not_active Ceased
- 2015-09-15 AU AU2015317877A patent/AU2015317877A1/en not_active Abandoned
- 2015-09-15 JP JP2017533742A patent/JP2017534673A/ja active Pending
- 2015-09-15 US US15/510,218 patent/US20170246148A1/en not_active Abandoned
-
2021
- 2021-01-11 US US17/146,360 patent/US20210379017A1/en not_active Abandoned
- 2021-01-29 AU AU2021200583A patent/AU2021200583A1/en not_active Abandoned
- 2021-08-10 JP JP2021130488A patent/JP2021181473A/ja active Pending
-
2023
- 2023-02-10 AU AU2023200727A patent/AU2023200727A1/en not_active Abandoned
- 2023-09-29 JP JP2023168970A patent/JP2023169413A/ja active Pending
- 2023-10-06 US US18/482,623 patent/US20240050409A1/en active Pending
-
2025
- 2025-03-06 AU AU2025201645A patent/AU2025201645A1/en active Pending